Skip to content
Search AI Powered

Latest Stories

Canopy Growth Files Lawsuit Against GW Pharma Over Intellectual Property Claims

This is a lawsuit you'll want to keep your eye on.
This is a lawsuit you'll want to keep your eye on.
Photo by Melinda Gimpel on Unsplash

This article was first published with Benzinga by Nina Zdinjak.

Canadian cannabis giant Canopy Growth Corp filed a federal lawsuit last week against Britain’s GW Pharma.


In the lawsuit filed in the U.S. District Court for the Western District of Texas, Canopy accuses GW Pharma of unauthorized usage of Canopy’s intellectual property related to a CBD extraction method.

Canopy Growth said it has obtained the intellectual property with its acquisition of Germany’s C3 Cannabinoid Compound Co. in 2019 for more than $250 million, reports Marijuana Business Daily. The same day the lawsuit was filed, Canopy was issued the U.S. patent.

According to Canopy, GW Pharma has been relying on the extraction method in question for the production of its flagship epilepsy drug Epidiolex.

Canopy said that “GW has been monitoring the ’632 Patent family for over fourteen years.”

The complaint has only one goal, which is to end GW’s “unauthorized use of Canopy’s intellectual property” — not to limit “patient access to Epidiolex,” Canopy said. 

Epidiolex is the first FDA-authorized CBD medicine for treating children with severe forms of epilepsy. The medicine was first approved for treatments of seizures connected to Lennox-Gastaut syndrome and Dravet syndrome.

In July, the FDA also approved Epidiolex for managing seizures related to tuberous sclerosis complex.

“As a policy, we do not comment on any pending litigation except to say that based on our preliminary review of the complaint, we are confident in our position and will vigorously defend against this lawsuit,” GW Pharma said in a statement emailed to Marijuana Business Daily.

Are you still missing out on The Bluntness newsletter? Sign Up today to stay in the loop.

More For You

Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Cannabis Glossary: 120+ Terms

Cannabis terminology can be overwhelming for new consumers. This glossary defines 120+ essential terms including cannabinoids (THC, CBD), consumption methods (vaping, edibles), and industry concepts to help you navigate dispensaries and products confidently.

Why Cannabis Terminology Matters

Cannabis terminology can feel overwhelming when you first step into a dispensary or browse online menus. Understanding the language helps you:

  • Communicate effectively with budtenders and medical professionals
  • Make informed decisions about products and consumption methods
  • Navigate dispensary menus with confidence
  • Understand product labels and lab results
  • Find products that match your needs and preferences
  • Stay safe by recognizing quality indicators and potential issues

This glossary provides clear, accurate definitions for over 120 cannabis terms, from basic concepts to advanced cultivation and processing terminology. Whether you're a first-time consumer or an experienced enthusiast, this guide will enhance your cannabis knowledge.

Keep Reading Show less
Navigating the Obstacles to Cannabis Legalization | The Edge ft Sen. Liz Krueger
Navigating the Obstacles to Cannabis Legalization | The Edge ft Sen. Liz Krueger
The Bluntness, Inc.
image of Drug Enforcement Agency Special Agent Badge

President Trump has just rescheduled marijuana - the biggest federal cannabis shift in 50 years - The Bluntness

Rescheduling vs. Descheduling Marijuana
image of prescription pill bottle with medicinal cannabis surrounding it

How Many Marijuana Strains Are There? Why There’s No Exact Number - The Bluntness

Photo by Jeff W on Unsplash